Healthcare / BiotechnologyStockholm
$3.94
+0.23 (+6.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-13.2M · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-252.9%
↓Gross Margin
83.8%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+196.1%
FCF CAGR
—
FCF margin
-34.0%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.3M · net income $-8.1M · FCF $-4.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.3M | $12.3M | $6.6M | $2.8M | $473000.00 |
| Net Income | $-8.1M | $-8.1M | $-13.7M | $-21.1M | $-22.7M |
| EBITDA | $-4.1M | $-4.1M | $-10.5M | $-17.0M | $-17.9M |
| EPS | -0.32 | -0.32 | -0.59 | -1.13 | -1.89 |
| Gross Margin | 83.8% | 83.8% | 72.8% | 58.8% | -11.6% |
| Operating Margin | -52.6% | -52.6% | -194.9% | -717.1% | -4421.1% |
| Net Margin | -65.6% | -65.6% | -208.9% | -747.4% | -4808.9% |
| Balance Sheet | |||||
| Current Ratio | 0.79 | 0.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.2M | $-4.2M | $-13.2M | $-18.9M | $-19.8M |
| Returns | |||||
| ROE | -252.9% | -252.9% | -229.4% | -191.2% | -162.6% |
| Valuation | |||||
| P/B | 31.48 | 31.48 | 6.48 | 4.43 | 4.38 |
| Growth & Yield | |||||
| Revenue Growth | 87.1% | 87.1% | 132.7% | 496.6% | — |
| EPS Growth | 46.1% | 46.1% | 48.2% | 40.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+100.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.59 → -0.32
Residual
+100.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.